Gene editing and many other useful biotechnology tools came from studies of bacteria fighting off viral invaders. But ...

The agreement grants Jumpcode access to ERS' CRISPR/Cas9 patent portfolio, empowering the company to advance the sensitivity and efficiency of next-generation sequencing (NGS) and expand ...

SKUAST-K is committed to producing a workforce that can drive innovation, enhance agricultural productivity, and address ...

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are CRISPR ...

The company is dedicated to creating a pipeline of in vivo medicines for serious diseases and holds exclusive licenses to key CRISPR patents for human medicines. The transition comes at a pivotal ...

Later, Wacław Szybalski popularized the term in 1974 in reference to genetic engineering, but little did he know that one day ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

The company is dedicated to creating a pipeline of in vivo medicines for serious diseases and holds exclusive licenses to key CRISPR patents for human medicines. The transition comes at a pivotal time ...

These patents include 12 patents related to LVVs ... competition from a multitude of gene-editing biotechs leveraging the CRISPR platform. CRISPR is a new gene editing platform that has recently ...

Investigators from Mass General Brigham and Beth Israel Deaconess Medical Center have developed STITCHR, a new gene editing tool that can insert therapeutic genes into specific locations without ...